[Therapy of idiopathic oligozoospermia with bromicriptine. Results of a prospective controlled study].
The effect of bromocriptin on semen parameters and endocrine profiles in 25 males presenting idiopathic oligozoospermia was evaluated in a prospective controlled clinical trial versus 25 patients treated with placebo. Following results were obtained: a) Serum concentrations of prolactin decreased significantly during bromocriptin treatment while FSH, LH and Testosterone concentration remained unchanged. b) Sperm count, motility and morphology were not significantly affected by bromocriptin versus placebo. c) Conception rate was not significantly different between the treatment and placebo group. From the results of this study it can be concluded that bromocriptin is no suitable agent in the treatment of idiopathic, normoprolactinemic oligozoospermia.
D000328:Adult; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D012739:Gonadal Steroid Hormones / Q000097:blood; D006801:Humans; D008297:Male; D009845:Oligospermia / Q000188:drug therapy*; D011446:Prospective Studies; D012661:Semen / Q000187:drug effects; D013076:Sperm Count; D013081:Sperm Motility / Q000187:drug effects
D012739:Gonadal Steroid Hormones; D001971:Bromocriptine
Therapie der idiopathischen Oligozoospermie mit Bromokriptin Resultate einer prospektiv kontrollierten Studie.